Accellix

Accellix provides a rapid, easy-to-use, automated cell phenotyping platform for quality control in cell and gene therapy.

Health Tech & Life Sciences
Acquired by bioMérieux
Series D Jerusalem, Israel Founded 2007
Last updated 2026-07-26
Total raised
$18.1M
Last: Undisclosed Round 2020-06
Stage
Series D
Founded
2007
Headcount
70
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences

About

Accellix developed a compact flow cytometry platform that delivers rapid, accurate, and automated cell phenotyping results for quality control in cell and gene therapy manufacturing and blood characterization. The platform automates the entire QC workflow from sample preparation to data analysis, aiming to simplify and standardize cellular analysis. Accellix was acquired by bioMérieux in January 2026 for approximately $38 million.

Funding history · 7 rounds · $18.1M total

2020-05
D Round $9.5M
★ bioMrieux,
2014-05
B Round $7.0M
★ Axcel Partners
2012-03
A Round Extension $1.6M
2010-07
A Round Extension Undisclosed
2010-05
Debt Financing Undisclosed
2009-08
A Round Undisclosed
2009-06
Seed Undisclosed

Headcount over time

From 22 (2019-03) to 70 (2026-07) · +48 (+218%) · 52 points · source: Finder history + radar grounding
730 2019-03 2026-07

Q&A

What is Accellix's primary business?
Accellix provides a rapid, easy-to-use, automated cell phenotyping platform for quality control in cell and gene therapy manufacturing and blood characterization.
When was Accellix acquired and by whom?
Accellix was acquired by bioMérieux in January 2026 for approximately $38 million.
What was Accellix's most recent funding round?
Accellix raised a D Round of $10,000,000 in December 2021, with BroadOak Capital Partners as a lead investor.
How many employees does Accellix currently have?
Accellix has 51–200 employees.
What was a significant funding event for Accellix in 2020?
In June 2020, Accellix raised a $9.5 million Series D round with lead investors bioMérieux and existing major investors.
Did Accellix secure any debt financing recently?
In April 2020, Accellix secured $8.5 million in convertible debt financing from existing major investors.
What was a key product development announced by Accellix in 2020?
In April 2020, Accellix announced its next-generation Accellix Instrument and Consumable, designed to further simplify and automate the QC workflow in cell therapy manufacturing.

Team · 1

Founder · Founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesDiagnostics Devices
Technologies
Platforms & InterfacesSoftware
Target customers
ConsumersDemographics & FamilyBabiesHealthcare & Life SciencesHealthcareProvidersLaboratories
Business model
B2B

Highlights

1 Patents

Tags

medical-technologieshospitalsreal-timemedical-deviceslaboratoriescritical-careblood-testbiomarkersdiagnosticsoperating-roomsdata-analyticssoftware-developmentdoctorsimmunotherapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteaccellix.com
LinkedInlinkedin.com/company/19221336
Facebookfacebook.com/Accellix-by-LeukoDx-1630405383882153
YouTubeyoutube.com/channel/UCViMRT-DKhzvqevPlWZnxHQ

Identifiers & details

Legal nameAccellix, Inc.
Former namesLeukoDx
Founded2007
Employees (exact)70
OfficesSan Jose

Acquisitions & public offerings

Acquired by bioMérieux 2026-01 $38.0M

Radar intelligence

Patents

EPO5

Web history (Wayback)

Domainaccellix.com

Certificate / subdomain footprint

Subdomains8

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514248251
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2009-03-02
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2024
Active charges / liens0
Registry events3 — people (2), charge (1)
Registered addressהלוי שלמה (מומו) 5 ירושלים

Recent registry events

DateEvent
2025-07-25עדכון דירקטורים-הסרת דירקטור
2025-07-25עדכון דירקטורים-הוספת דירקטור
2026-01-15סילוק שעבוד